Bioprocess simulation meets real‑world scale‑up in New Wave‑Nurasa deal
UK‑based bioprocess simulation specialist New Wave Biotech has entered a commercial partnership with Nurasa, the Temasek‑owned sustainable food and nutrition company, in a move designed to speed up the journey from lab‑scale innovation to commercially viable food and ingredient production.
The collaboration brings together New Wave Biotech’s AI‑driven bioprocess modelling tools with Nurasa’s Asia‑wide innovation ecosystem, creating a combined digital‑to‑physical pathway aimed at reducing scale‑up risk for emerging sustainable food technologies.
The partnership targets three persistent challenges in the sustainable food and bio-manufacturing sectors:
1 Predicting downstream performance without lengthy, costly experimentation
2 Translating technical decisions into clear cost, yield and sustainability outcomes
3 Turning novel ingredients into market‑ready products with credible commercial pathways.
Nurasa’s network of companies will gain access to New Wave Biotech’s Bioprocess Foresight platform, enabling teams to virtually test thousands of downstream processing scenarios and run automated techno‑economic analysis (TEA) and life‑cycle assessment (LCA). This gives innovators early visibility into cost structures, environmental impact and process bottlenecks – long before committing to major infrastructure or manufacturing investment.
New Wave Biotech’s modelling tools have demonstrated the ability to reduce physical experimentation by up to 90% and halve unit costs, offering a powerful lever for ingredient companies navigating the high‑risk transition from R&D to commercial scale.
Nurasa will complement these digital capabilities with its food‑grade pilot facilities, product development expertise, regulatory support and go‑to‑market partnerships across Asia. This creates a full‑stack support system for food‑tech and ingredient companies seeking to scale production or enter Asian markets.
“Singapore is strengthening its position as a hub for scalable, sustainable nutrition and biomanufacturing innovation,” said Samson Lee, strategic partnerships manager at Nurasa. “Integrating New Wave Biotech’s simulation and TEA/LCA capabilities strengthens our ability to guide start-ups and corporates toward commercially viable production, not just technical validation.”
For New Wave Biotech, the partnership expands its reach into Asia while providing customers with access to real‑world scale‑up environments that complement its digital modelling tools.
“Scaling biomanufacturing depends on understanding not just how a process behaves, but what that means for cost, yield and sustainability,” said Zoe Yu Tung Law, co‑founder and CEO of New Wave Biotech. “By partnering with Nurasa, we can help companies progress from lab to commercially viable manufacturing with far greater clarity and lower risk.”
By linking predictive digital modelling with physical pilot‑scale infrastructure and market access, the partnership aims to accelerate the development of sustainable nutrition and bio-manufactured ingredients across Asia and Europe – supporting a new generation of food‑tech companies working to reduce environmental impact while scaling responsibly.
